Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167440 | 1.00 | BRD4 (0.42) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL371025 | 1.00 | BRD4 (0.42) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL343711 | 0.92 | JAK2 (0.41) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL343712 | 0.92 | JAK2 (0.41) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL10167438 | 0.92 | JAK2 (0.41) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL343262 | 0.83 | SYK (0.41) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL343261 | 0.83 | SYK (0.41) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL371146 | 0.83 | BRD4 (0.35) | BRD4 | |
| SCHEMBL10167369 | 0.81 | SYK (0.40) | BRD4TTKJAK1JAK2TYK2 | |
| SCHEMBL344726 | 0.78 | CDK1 (0.42) | JAK1JAK2TYK2AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | claimed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | BRD4 602/4885TTK 226/4885JAK1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.